Mariam Sarwar
Overview
Mariam Sarwar is an associate in the firm’s Litigation and Trial group. Her work encompasses litigation matters across a variety of industries in the areas of complex commercial litigation, copyright and trademark infringement, unfair competition, trade secrets, false advertising, products liability, and consumer class actions. She has experience providing investigation and litigation issues analysis, as well as counseling on regulatory compliance. Mariam frequently advises clients on compliance, litigation, and enforcement matters involving the Food and Drug Administration. Her work helps clients navigate issues of product safety and recalls, advertising, marketing, labeling, and consumer protection.
Career & Education
- Kalamazoo College, B.A., 2009
- Loyola Law School, Los Angeles, J.D., 2019
- California
- Member, Pro Bono Advisory Council, Asian Americans Advancing Justice Southern California
Mariam's Insights
Client Alert | 4 min read | 05.07.24
The Food and Drug Administration (FDA) has published revised draft guidelines in the Federal Register on promotional labeling and advertising considerations for the biologic and biosimilar industry, updating guidance from 2020. The quick revisions emphasize the fast-changing and rapidly growing nature of this industry.
Client Alert | 3 min read | 01.11.24
FDA Issues Final Guidance on Direct-to-Consumer Prescription Drug Advertisements
Publication | 12.14.22
Representative Matters
- Representing an aviation industry client in a complex trade secrets case involving the development of hardware and software for avionics display units.
- Won summary judgment on behalf of a manufacturing company in a trade secrets litigation.
- Represented an automobile company in various class action lawsuits alleging vehicle defects and obtained multiple dismissals of class action claims on motion to dismiss and summary judgment, including an affirmation of summary judgment dismissal by the Ninth Circuit Court of Appeal.
- Represented a healthcare company in multiple products liability class action lawsuits, successfully obtaining favorable settlements and/or dismissals.
- Represented a major beverage company in a class action lawsuit relating to allegedly misleading advertising based on ingredient claims.
Mariam's Insights
Client Alert | 4 min read | 05.07.24
The Food and Drug Administration (FDA) has published revised draft guidelines in the Federal Register on promotional labeling and advertising considerations for the biologic and biosimilar industry, updating guidance from 2020. The quick revisions emphasize the fast-changing and rapidly growing nature of this industry.
Client Alert | 3 min read | 01.11.24
FDA Issues Final Guidance on Direct-to-Consumer Prescription Drug Advertisements
Publication | 12.14.22
Insights
High-ly Sensitive Information: Use of FDA’s DMF Process to Protect Cannabis Trade Secrets
|06.17.21
Crowell & Moring’s Trade Secrets Trends
- |
09.11.20
Crowell & Moring’s Retail & Consumer Products Law Observer
NHTSA versus CPSC Jurisdiction Over Certain Micromobility Products
|09.02.20
Crowell & Moring’s Retail & Consumer Products Law Observer
Mariam's Insights
Client Alert | 4 min read | 05.07.24
The Food and Drug Administration (FDA) has published revised draft guidelines in the Federal Register on promotional labeling and advertising considerations for the biologic and biosimilar industry, updating guidance from 2020. The quick revisions emphasize the fast-changing and rapidly growing nature of this industry.
Client Alert | 3 min read | 01.11.24
FDA Issues Final Guidance on Direct-to-Consumer Prescription Drug Advertisements
Publication | 12.14.22
